Solutions

COMMENTARY: Foreign leaders discussing solutions to the Ebola epidemic must acknowledge the contribution made by local workers to reduce infection rates

     International response … leaders of Ebola-hit countries in west Africa and EU commissioners attend a conference in    Brussels on Ebola on Tuesday 3 March. Photograph: Thierry Charlier/AFP/Getty Images

THE GUARDIAN by James Fofanah                                                                    March 3, 2015

...The international community’s initial focus on a purely medical response – and a megaphone broadcast of the over-simplistic message that “Ebola is real” – was a failure, and a major reason for the rapid spread of the disease at the early-to-middle stages of the epidemic.

FORBES   by   David Kroll                                                                                          March 1, 2015

The widely-discussed antibody cocktail, ZMapp, is finally going to be tested under standardized, controlled conditions for its safety and efficacy in Ebola virus disease-infected patients in Liberia and, potentially, the United States.

Late Friday, the NIH National Institute of Allergy and Infectious Disease (NIAID) announced the launch of a randomized trial in up to 200 patient volunteers with confirmed Ebola virus infections.

The two-arm study will compare supportive standard of care with or without three intravenous infusions of ZMapp spaced three days apart. This is the same dosing regimen published in Nature that protected 18 of 18 monkeys when given up to five days after experimental infection.

LeafBio, the commercial arm of San Diego-based Mapp Biopharmaceutical, announced concomitantly that the FDA had approved their IND for this trial. The three antibodies that comprise ZMapp target both distinct and overlapping parts of the Ebola virus glycoprotein (GP) that it uses to infect humans.

REUTERS                                                           Feb. 26, 2015

Diagnostics company Corgenix Medical Corp said on Thursday U.S. health regulators had approved its rapid Ebola test for emergency use, in response to the world's worst outbreak of the virus that killed more than 10,000 so far.

The company's ReEBOV Antigen Rapid Test, which involves putting a drop of blood on a paper strip and waiting for at least 15 minutes for a reaction, was cleared by the World Health Organization last week.

The test is less accurate than the standard test, which has a turnaround time of 12-24 hours, but is easy to perform and does not require electricity. It is able to correctly identify about 92 percent of Ebola-infected patients and 85 percent of those not infected with the virus, the WHO said.

The WHO is still assessing four or five other rapid test candidates.

Read complete story.
http://www.reuters.com/article/2015/02/26/us-health-ebola-testing-idUSKBN0LU1OO20150226

submitted by George Hurlburt

A new paper diagnostic device can detect Ebola as well as other viral hemorrhagic fevers in about 10 minutes. The device (pictured here) has silver nanoparticles of different colors that indicate different diseases. On the left is the unused device, opened to reveal the contents inside. On the right, the device has been used for diagnosis; the colored bands show positive tests.  Photo - Jose Gomez-Marquez, Helena de Puig, and Chun-Wan Yen

Simple paper strip can diagnose Ebola and other fevers within 10 minutes

CLICK HERE - Lab on a Chip - Multicolored silver nanoparticles for multiplexed disease diagnostics: distinguishing dengue, yellow fever, and Ebola viruses

Massachusetts Institute of Technology (MIT) - eurekalert.org - February 24, 2015

CAMBRIDGE, MA -- When diagnosing a case of Ebola, time is of the essence. . .

. . . A new test from MIT researchers . . . The device, a simple paper strip similar to a pregnancy test, can rapidly diagnose Ebola, as well as other viral hemorrhagic fevers such as yellow fever and dengue fever. . .